It is against this backdrop an analyst at Mizuho Securities said Scana shares look attractive and offer roughly 26-percent total upside in the firm's base-case scenario.
Analyst Paul Fremont upgraded SCANA Corp. from Hold to Buy and maintained a $46 price target.
Scana represents a good value proposition given the likelihood of significant upside to the extent the company is successful in a court challenge to the rate cut announced by the South Carolina legislature, Fremont said in a Friday note. (See the analyst's track record here.)
The state had announced a 15-percent mandated rate reduction.
A strong likelihood exists of a stay being issued in the case, the analyst said.
"The standalone earnings of Scana will be higher if they are successful in obtaining a temporary stay in the Circuit Court," Fremont said.
Scana has a viable legal argument in the form of unconstitutional taking for the overturning of the rate-cut legislation, the analyst said.
Mizuho adjusted its earnings estimates to reflect the 15-percent annual reduction effective April 1, 2018. This would result in earnings per share of $2.69 in 2020.
"A favorable court ruling in their challenge of HB 4375 would likely put pressure on the South Carolina Commission to leave intact prior BLRA authorized rate increases," Fremont said.
If Dominion walks away from its purchase of Scana, Fremont said other potential buyers would make an offer on the company.
The Price Action
SCANA shares are flat year-to-date.
The stock was trading up 1.47 percent to $39.04 at the time of publication Friday.
FERC Ruling Casts Doubts On Dominion's Dropdown Ambitions, BofA Says In Downgrade
Some Traders Betting The Energy Rally Is On Borrowed Time
Latest Ratings for SCG
|May 2018||Williams Capital||Downgrades||Hold||Sell|
|Apr 2018||Williams Capital||Upgrades||Sell||Hold|
View More Analyst Ratings for SCG
View the Latest Analyst Ratings
See more from Benzinga
- Benzinga's Daily Biotech Pulse: Gemphire On Fire, Acceleron-Celgene Taste Success, AbbVie Ditches Galapagos
- Benzinga's Daily Biotech Pulse: Eli Lilly, Edge Therapeutics, BioXcel Report Positive Trial Results, 4 Stocks Debut
- Benzinga's Daily Biotech Pulse: Pain Therapeutics Drops 70%, Neon To Begin Trading
© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.